Dramatic advances in immune therapy have emerged as a promising strategy in cancer therapeutics. In addition to chemotherapy and radiotherapy, inhibitors targeting immune-checkpoint molecules such as cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed cell death receptor-1 (PD-1) and its ligand (PD-L1) demonstrate impressive clinical benefits in clinical trials. In this review, we present background information about therapies involving PD-1/PD-L1 blockade and provide an overview of current clinical trials. Furthermore, we present recent advances involving predictive biomarkers associated with positive therapeutic outcomes in cancer immunotherapy.

Original languageEnglish
Article number96
JournalJournal of Biomedical Science
Issue number1
Publication statusPublished - Dec 5 2019


  • Cancer immunotherapy
  • Checkpoint inhibitor
  • PD-1 PD-L1 signaling

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Molecular Biology
  • Clinical Biochemistry
  • Cell Biology
  • Biochemistry, medical
  • Pharmacology (medical)


Dive into the research topics of 'Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway'. Together they form a unique fingerprint.

Cite this